Psychedelic drugs are experiencing a renaissance in clinical research, due in part to the increasing prevalence of psychiatric and mental health disorders and changing attitudes towards the use of these substances in medicine. With renewed investment and engagement in this area, the body of evidence to support the clinical use of psychedelics is growing and industry is moving closer to realising the potential of these innovative drugs to treat patients with a range of debilitating disorders. Nancy Cross, Senior Analyst at Lightning Health, provides a brief background on psychedelics and their use in medicine and clinical research.